Navitor Pharmaceuticals reported a $23.5 million Series A financing.
According to a company release, proceeds from the financing will be used to augment Navitor's proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient signaling via the mTORC1 pathway to address a range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. Investors in the Series A financing include Polaris Partners, Atlas Venture, Johnson & Johnson Development Corp., SR One and The Longevity Fund.
"With a proprietary platform and a world-class scientific team, Navitor is uniquely positioned to target newly discovered nutrient signaling mechanisms that drive protein synthesis and cellular growth. We are harnessing this approach to develop novel therapeutics to treat a wide range of chronic diseases and rare disorders," said George P. Vlasuk, PhD, President and Chief Executive Officer of Navitor.
Navitor noted its proprietary drug discovery platform is designed to develop selective modulators of mTORC1, which control the cell's central signaling in response to nutrient availability, particularly amino acids. The selective modulation of mTORC1 offers a new and targeted approach to create new medicines for a variety of clinical indications and to significantly expand the therapeutic potential of a clinically validated pathway.
"Navitor represents a rare convergence of innovative science, world-class scientific advisors, and an experienced team with the potential to create significant value based on breakthrough science," said Alan Crane, Founder and Chairman of Navitor and a Partner at Polaris Partners. "We are excited to be a part of building a biopharmaceutical company with the potential to offer new approaches to treat a wide range of important diseases and have a significant impact for patients."
Navitor Pharmaceuticals is a biopharmaceutical company.
More Information and complete details:
((Comments on this story may be sent to firstname.lastname@example.org))